These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Worries about animal models in biomedical research: a response to LaFollette and Shanks. Willis LR; Hulsey MG Public Aff Q; 1994 Apr; 8(2):205-18. PubMed ID: 11652920 [No Abstract] [Full Text] [Related]
7. Two new efforts to inform patients about drugs launch a post-PPI era. Med World News; 1982 Sep; 23(20):8-9. PubMed ID: 11645760 [No Abstract] [Full Text] [Related]
8. Some thoughts on the generic equivalency debate. Berry FB Med Times; 1971 Sep; 99(9):199-201. PubMed ID: 5170858 [No Abstract] [Full Text] [Related]
9. Preparation and use of drug master files in the pharmaceutical industry. Personeus GR; Ascione P J Parenter Sci Technol; 1981; 35(2):63-9. PubMed ID: 7229835 [No Abstract] [Full Text] [Related]
10. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation. Daemmrich A Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740 [No Abstract] [Full Text] [Related]
12. Advantages of universal coding and classification system for drugs. Drug classification activities of the American Medical Association. Seitner PG Am J Hosp Pharm; 1966 Feb; 23(2):88-92. PubMed ID: 5952046 [No Abstract] [Full Text] [Related]
13. New drugs and the Kefauver-Harris amendment. Krantz JC J New Drugs; 1966; 6(2):77-9. PubMed ID: 5917906 [No Abstract] [Full Text] [Related]
15. Drugs, devices, diagnostics, and policies: the year's review. Kupecz D Nurse Pract; 2000 Feb; 25(2):42, 45-8, 51-3; quiz 54-5. PubMed ID: 10703024 [TBL] [Abstract][Full Text] [Related]
16. Drugs of limited commercial value. Van Woert MH N Engl J Med; 1980 Jul; 303(2):114. PubMed ID: 7383068 [No Abstract] [Full Text] [Related]
17. Understanding the FDA's guarded system for classifying new drugs. Schneiweiss F Hosp Pharm; 1979 May; 14(5):262-4, 266, 268 passim. PubMed ID: 10316828 [No Abstract] [Full Text] [Related]
18. The FDA's response to AIDS: paradigm shift in new drug policy? Podraza R Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267 [No Abstract] [Full Text] [Related]
19. FDA's new rule on treatment use and sale of investigational new drugs. Levine RJ IRB; 1987; 9(4):1-4. PubMed ID: 11649946 [No Abstract] [Full Text] [Related]